These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28744014)

  • 21. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
    Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
    Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
    Nielsen I; Hasselbalch HC
    Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
    Chauvet P; Nibourel O; Berthon C; Goursaud L; Carpentier B; Lionne-Huyghe P; Wemeau M; Quesnel B
    Leuk Res; 2022 Jul; 118():106871. PubMed ID: 35633618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TP53 mutations in older adults with acute myeloid leukemia.
    Yanada M; Yamamoto Y; Iba S; Okamoto A; Inaguma Y; Tokuda M; Morishima S; Kanie T; Mizuta S; Akatsuka Y; Okamoto M; Emi N
    Int J Hematol; 2016 Apr; 103(4):429-35. PubMed ID: 26781615
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Bomben R; Rossi FM; Vit F; Bittolo T; D'Agaro T; Zucchetto A; Tissino E; Pozzo F; Vendramini E; Degan M; Zaina E; Cattarossi I; Varaschin P; Nanni P; Berton M; Braida A; Polesel J; Cohen JA; Santinelli E; Biagi A; Gentile M; Morabito F; Fronza G; Pozzato G; D'Arena G; Olivieri J; Bulian P; Pepper C; Hockaday A; Schuh A; Hillmen P; Rossi D; Chiarenza A; Zaja F; Di Raimondo F; Del Poeta G; Gattei V
    Clin Cancer Res; 2021 Oct; 27(20):5566-5575. PubMed ID: 34285062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
    Quesada AE; Routbort MJ; DiNardo CD; Bueso-Ramos CE; Kanagal-Shamanna R; Khoury JD; Thakral B; Zuo Z; Yin CC; Loghavi S; Ok CY; Wang SA; Tang Z; Bannon SA; Benton CB; Garcia-Manero G; Kantarjian H; Luthra R; Medeiros LJ; Patel KP
    Am J Hematol; 2019 Jul; 94(7):757-766. PubMed ID: 30963592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
    Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
    Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Ball S; Loghavi S; Zeidan AM
    Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
    Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
    Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
    Zhang L; Dong H
    Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
    Lundberg P; Karow A; Nienhold R; Looser R; Hao-Shen H; Nissen I; Girsberger S; Lehmann T; Passweg J; Stern M; Beisel C; Kralovics R; Skoda RC
    Blood; 2014 Apr; 123(14):2220-8. PubMed ID: 24478400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK2V617F mutations in myeloid malignancies: single center experience.
    Panovska-Stavridis I; Cevreska L; Ivanovski M; Stojanovik A; Lozance M; Matevska N; Dimovski A; Serafimoski V
    Prilozi; 2008 Dec; 29(2):257-67. PubMed ID: 19259051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.
    Zhao D; Eladl E; Zarif M; Capo-Chichi JM; Schuh A; Atenafu E; Minden M; Chang H
    Cancer Med; 2023 Mar; 12(6):6511-6522. PubMed ID: 36394085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
    Shah MV; Tran ENH; Shah S; Chhetri R; Baranwal A; Ladon D; Shultz C; Al-Kali A; Brown AL; Chen D; Scott HS; Greipp P; Thomas D; Alkhateeb HB; Singhal D; Gangat N; Kumar S; Patnaik MM; Hahn CN; Kok CH; Tefferi A; Hiwase DK
    Blood Cancer J; 2023 Apr; 13(1):51. PubMed ID: 37041128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.
    Venton G; Courtier F; Charbonnier A; D'incan E; Saillard C; Mohty B; Mozziconacci MJ; Birnbaum D; Murati A; Vey N; Rey J
    Am J Hematol; 2018 Mar; 93(3):330-338. PubMed ID: 29148089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
    Malcikova J; Pavlova S; Kunt Vonkova B; Radova L; Plevova K; Kotaskova J; Pal K; Dvorackova B; Zenatova M; Hynst J; Ondrouskova E; Panovska A; Brychtova Y; Zavacka K; Tichy B; Tom N; Mayer J; Doubek M; Pospisilova S
    Blood; 2021 Dec; 138(25):2670-2685. PubMed ID: 33945616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.